Cover Image
市場調查報告書

轉移癌症治療藥的全球市場分析、預測

Global Metastatic Cancer Treatment Market: Focus on Drugs, Competitive Landscape and Country - Analysis and Forecast 2018-2025

出版商 BIS Research Private Limited 商品編碼 658948
出版日期 內容資訊 英文 377 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
轉移癌症治療藥的全球市場分析、預測 Global Metastatic Cancer Treatment Market: Focus on Drugs, Competitive Landscape and Country - Analysis and Forecast 2018-2025
出版日期: 2018年07月03日 內容資訊: 英文 377 Pages
簡介

全球轉移癌症治療藥的市場預計從2017年的541億1000萬美元,成長到2025年982億4000萬美元的規模。

本報告提供全球轉移癌症治療藥的市場調查,市場背景、概要,市場成長的各種影響因素及市場機會分析,競爭環境與企業策略,相關法律,核准、指定趨勢,開發平台趨勢,各治療對象、產品、地區的趨勢與市場規模的變化與預測,主要企業簡介等彙整資料。

摘要整理

第1章 市場概要

  • 關於癌症
  • 癌症統計
  • 轉移與轉移癌症
  • 全球市場
  • FDA核准
  • 前提條件、規定

第2章 市場動態

  • 影響分析
  • 成長推動因素
  • 阻礙成長要素
  • 市場機會

第3章 產業分析

  • 簡介
  • 法律規章方案
  • 法律規章上的指定
  • 專利環境

第4章 競爭環境

  • 簡介
  • 主要的部署、策略
    • 核准
    • 臨床試驗
    • 協定、聯盟、JV、合作
    • 指定
    • 收購、產品推出、其他
  • 波特的五力分析
  • 市場佔有率
  • 開發平台分析

第5章 全球轉移癌症治療藥市場分析、預測:各治療對象

  • 概要
  • 乳癌
  • 黑色素瘤
  • 前列腺癌
  • 肺癌
  • 大腸癌
  • 其他癌症

第6章 全球轉移癌症治療藥市場分析、預測:各產品

  • 概要
    • 學名藥 vs 品牌藥
  • 品牌藥的重要性
  • 學名藥的重要性
  • 癌症治療藥的銷售額

第7章 全球轉移癌症治療藥市場分析、預測:各地區

  • 概要
    • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 印度
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 其他地區

第8章 企業簡介

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • BRISTOL-MYERS SQUIBB COMPANY
  • CELGENE CORPORATION
  • Eli-Lilly and Company
  • F. Hoffmann-La Roche AG
  • JOHNSON & JOHNSON
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SANOFI
  • 武田藥品工業
  • bluebird bio, Inc.
  • Clovis Oncology, Inc.
  • IDERA PHARMACEUTICALS, INC.
  • eTheRNA immunotherapies NV

第9章 調查範圍、調查手法

第10章 附錄

目錄
Product Code: BH061A

The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is anticipated to reach $98.24 billion by 2025.

The healthcare industry is a multi-billion dollars market consisting of various verticals aimed at improving patient lives. With increase in research and developmental activities, technological advancements are being made to make patient services convenient and affordable. Cancer represents one of the major concern of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). Cancer statistics has a major impact on society across the world and accounts for almost 70% of death in low- and middle- income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, enormous scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of metastatic cancer treatment market. Metastatic cancer, represents the advanced form of cancer, which occurs when the cancer cells starts spreading from the primary site of origin to different parts of the body. Treatment of metastatic cancer is often not curable and is mainly focussed on providing palliative care. Several companies are investing into oncology market and are making strenuous effort for the delivery of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to arrest their condition, which is turn is increasing the adoption rate of the metastatic cancer treatment drugs.

The metastatic cancer treatment market consists of products, such as generic medicines and branded medicines, used in the treatment of metastatic cancer. The market analysis includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, lung cancer, prostate cancer, and others. Geographically, the market can be segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Rest of the World.

The purpose of the study is to gain a holistic view of the global metastatic cancer treatment market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon conducting a detailed study of the solutions allied with metastatic cancer treatment market, which involves drugs used in different therapeutic applications of cancer treatment such as chemotherapy, hormone therapy, and immunotherapy, among others. The global metastatic cancer treatment market is segmented into three different parts: ‘by products', ‘by therapeutic indication', and ‘by region'. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global metastatic cancer treatment market, and assesses the factors governing the same. Opportunity matrix and detailed product mapping have been included in the report. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, restraints, and opportunities in the global metastatic cancer treatment market?
  • What are the market shares of the leading segments, and sub-segments of the global metastatic cancer treatment market in 2017 and what will be its value in 2026?
  • How will each segment of the global metastatic cancer treatment market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
  • What are the influencing factors that may affect the market share of the key players?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What are the major Regulatory Authorities/ Associations/ Consortiums affecting the metastatic cancer treatment market and what are the main designations facilitating development and approval of cancer drugs?
  • Which are the companies holding patent rights for the metastatic cancer treatment drugs and what patent landscape exist in the market?
  • Which product segment is expected to register the highest CAGR for the global metastatic cancer treatment market?
  • How has the market been segmented based on therapeutic indication? Which therapeutic indication segment has the largest share, and fastest growth rate in the global metastatic cancer treatment market?
  • Which geographical region will contribute to the highest sales of the metastatic cancer treatment drugs during the forecast period and which will have the highest CAGR?
  • What are major companies developing metastatic cancer treatment drugs targeted for different therapeutic indication and what were sales of drugs for the past three years (2015-2017)?
  • What are the drugs under developmental stages and the companies conducting their clinical study?

The key players that have been contributing significantly include: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi and Takeda Pharmaceutical Company Limited, among others.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Introduction to Cancer
  • 1.2. Cancer Statistics: Incidence, Survival and Mortality
    • 1.2.1. Important Facts
  • 1.3. Metastasis and Metastatic Cancer
    • 1.3.1. Where Cancer Spreads
    • 1.3.1. Ongoing Research and Treatment of Metastatic Cancer
  • 1.4. Global Market
  • 1.5. FDA Approvals of Oncology Drugs
  • 1.6. Assumptions and Limitation

2. Market Dynamics

  • 2.1. Market Dynamics: Impact Analysis
  • 2.2. Market Drivers
  • 2.3. Market Restraints
  • 2.4. Market Opportunities

3. Industry Insights

  • 3.1. Introduction
  • 3.2. Regulatory Scenario
  • 3.3. Regulatory Designations
  • 3.4. Patent Landscape

4. Competitive Landscape

  • 4.1. Introduction
  • 4.2. Key Developments and Strategies
    • 4.2.1. Product Approvals
    • 4.2.2. Clinical Study
    • 4.2.3. Agreement, Partnership, Joint Venture and Collaboration
    • 4.2.4. Regulatory Designations
    • 4.2.5. Acquisition, Product Launches and Others
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrant
    • 4.3.4. Threat of Substitute
    • 4.3.5. Intensity of Competitive Rivalry
  • 4.4. Market Share (2014-2017)
  • 4.5. Pipeline Analysis

5. Global Metastatic Cancer Treatment Market, By Therapeutic Application

  • 5.1. Overview
  • 5.2. Breast Cancer
    • 5.2.1. Breast Cancer: Types, Secondary Sites and Symptoms
      • 5.2.1.1. Breast Cancer: Molecular Subtypes
    • 5.2.2. Breast Cancer: Incidence, Mortality and Prevalence
    • 5.2.3. Breast Cancer: Market
    • 5.2.4. Breast Cancer: Treatment
  • 5.3. Melanoma
    • 5.3.1. Melanoma: Types, Secondary Sites and Symptoms
    • 5.3.2. Melanoma: Incidence, Mortality and Prevalence
    • 5.3.3. Melanoma: Market
    • 5.3.4. Melanoma: Treatment
  • 5.4. Prostate Cancer
    • 5.4.1. Prostate Cancer: Types, Secondary Sites and Symptoms
    • 5.4.2. Prostate Cancer: Incidence, Mortality and Prevalence
    • 5.4.3. Prostate Cancer: Market
    • 5.4.4. Prostate Cancer: Treatment
  • 5.5. Lung Cancer
    • 5.5.1. Lung Cancer: Types, Secondary Sites and Symptoms
    • 5.5.2. Lung Cancer: Incidence, Mortality and Prevalence
    • 5.5.3. Lung Cancer: Market
    • 5.5.4. Lung Cancer: Treatment
  • 5.6. Colorectal Cancer
    • 5.6.1. Colorectal Cancer: Types, Secondary Sites and Symptoms
    • 5.6.2. Colorectal Cancer: Incidence, Mortality and Prevalence
    • 5.6.3. Colorectal Cancer: Market
    • 5.6.4. Colorectal Cancer: Treatment
  • 5.7. Other Cancers

6. Global Metastatic Cancer Treatment Market, By Product

  • 6.1. Overview
    • 6.1.1. Generic vs. Branded Drugs
  • 6.2. Role of Branded Medicines in Oncology
    • 6.2.1. Branded Medicines: Market
  • 6.3. Role of Generic Medicines in Oncology
    • 6.3.1. Generic Medicines: Market
  • 6.4. Sales of Oncology Drugs

7. Global Metastatic Cancer Treatment Market, By Region

  • 7.1. Overview
    • 7.1.1. Introduction
  • 7.2. North America
    • 7.2.1. The U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. The U.K.
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
  • 7.4. Asia Pacific
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Argentina
  • 7.6. Rest of the World

8. Company Profiles

  • 8.1. AbbVie, Inc.
    • 8.1.1. Overview
    • 8.1.2. Overall Product Portfolio
      • 8.1.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.1.3. Financials
      • 8.1.3.1. Financial Summary
    • 8.1.4. Global Presence
    • 8.1.5. Recent Developments
    • 8.1.6. SWOT Analysis
  • 8.2. Amgen, Inc.
    • 8.2.1. Overview
    • 8.2.2. Overall Product Portfolio
      • 8.2.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.2.3. Financials
      • 8.2.3.1. Financial Summary
    • 8.2.4. Global Presence
    • 8.2.5. Recent Developments
    • 8.2.6. SWOT Analysis
  • 8.3. AstraZeneca PLC
    • 8.3.1. Overview
    • 8.3.2. Overall Product Portfolio
      • 8.2.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.3.3. Financials
      • 8.3.3.1. Financial Summary
    • 8.3.4. Global Presence
    • 8.3.5. Recent Developments
    • 8.3.6. SWOT Analysis
  • 8.4. Bayer AG
    • 8.4.1. Overview
    • 8.4.2. Overall Product Portfolio
      • 8.4.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.4.3. Financials
      • 8.4.3.1. Financial Summary
    • 8.4.4. Global Presence
    • 8.4.5. Recent Developments
    • 8.4.6. SWOT Analysis
  • 8.5. Boehringer Ingelheim International GmbH
    • 8.5.1. Overview
    • 8.5.2. Overall Product Portfolio
      • 8.5.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.5.3. Financials
      • 8.5.3.1. Financial Summary
    • 8.5.4. Global Presence
    • 8.5.5. Recent Developments
    • 8.5.6. SWOT Analysis
  • 8.6. BRISTOL-MYERS SQUIBB COMPANY
    • 8.6.1. Overview
    • 8.6.2. Overall Product Portfolio
      • 8.6.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.6.3. Financials
      • 8.6.3.1. Financial Summary
    • 8.6.4. Global Presence
    • 8.6.5. Recent Developments
    • 8.6.6. SWOT Analysis
  • 8.7. CELGENE CORPORATION
    • 8.7.1. Overview
    • 8.7.2. Overall Product Portfolio
      • 8.7.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.7.3. Financials
      • 8.7.3.1. Financial Summary
    • 8.7.4. Global Presence
    • 8.7.5. Recent Developments
    • 8.7.6. SWOT Analysis
  • 8.8. Eli-Lilly and Company
    • 8.8.1. Overview
    • 8.8.2. Overall Product Portfolio
      • 8.8.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.8.3. Financials
      • 8.8.3.1. Financial Summary
    • 8.8.4. Global Presence
    • 8.8.5. Recent Developments
    • 8.8.6. SWOT Analysis
  • 8.9. F. Hoffmann-La Roche AG
    • 8.9.1. Overview
    • 8.9.2. Overall Product Portfolio
      • 8.9.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.9.3. Financials
      • 8.9.3.1. Financial Summary
    • 8.9.4. Global Presence
    • 8.9.5. Recent Developments
    • 8.9.6. SWOT Analysis
  • 8.10. JOHNSON & JOHNSON
    • 8.10.1. Overview
    • 8.10.2. Overall Product Portfolio
      • 8.10.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.10.3. Financials
      • 8.10.3.1. Financial Summary
    • 8.10.4. Global Presence
    • 8.10.5. Recent Developments
    • 8.10.6. SWOT Analysis
  • 8.11. Merck & Co., Inc.
    • 8.11.1. Overview
    • 8.11.2. Overall Product Portfolio
      • 8.11.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.11.3. Financials
      • 8.11.3.1. Financial Summary
    • 8.11.4. Global Presence
    • 8.11.5. Recent Developments
    • 8.11.6. SWOT Analysis
  • 8.12. Novartis AG
    • 8.12.1. Overview
    • 8.12.2. Overall Product Portfolio
      • 8.12.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.12.3. Financials
      • 8.12.3.1. Financial Summary
    • 8.12.4. Global Presence
    • 8.12.5. Recent Developments
    • 8.12.6. SWOT Analysis
  • 8.13. Pfizer, Inc.
    • 8.13.1. Overview
    • 8.13.2. Overall Product Portfolio
      • 8.13.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.13.3. Financials
      • 8.13.3.1. Financial Summary
    • 8.13.4. Global Presence
    • 8.13.5. Recent Developments
    • 8.13.6. SWOT Analysis
  • 8.14. SANOFI
    • 8.14.1. Overview
    • 8.14.2. Overall Product Portfolio
      • 8.14.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.14.3. Financials
      • 8.14.3.1. Financial Summary
    • 8.14.4. Global Presence
    • 8.14.5. Recent Developments
    • 8.14.6. SWOT Analysis
  • 8.15. Takeda Pharmaceutical Company Limited
    • 8.15.1. Overview
    • 8.15.2. Overall Product Portfolio
      • 8.15.2.1. Product Offerings for Metastatic Cancer Treatment Market
    • 8.15.3. Financials
      • 8.15.3.1. Financial Summary
    • 8.15.4. Global Presence
    • 8.15.5. Recent Developments
    • 8.15.6. SWOT Analysis
  • 8.16. bluebird bio, Inc.
    • 8.16.1. Overview
    • 8.16.2. Product Offerings for Metastatic Cancer Treatment Market
  • 8.17. Clovis Oncology, Inc.
    • 8.17.1. Overview
    • 8.17.2. Product Offerings for Metastatic Cancer Treatment Market
  • 8.18. IDERA PHARMACEUTICALS, INC.
    • 8.18.1. Overview
    • 8.18.2. Product Offerings for Metastatic Cancer Treatment Market
  • 8.19. eTheRNA immunotherapies NV
    • 8.19.1. Overview
    • 8.19.2. Product Offerings for Metastatic Cancer Treatment Market

9. Report Scope and Methodology

  • 9.1. Scope of the Report
  • 9.2. Global Metastatic Cancer Treatment Market Segmentation
  • 9.3. Research Methodology
    • 9.3.1. Primary Research
    • 9.3.2. Secondary Research
    • 9.3.3. Key Data Points from Primary Sources
    • 9.3.4. Key Data Points from Secondary Sources
    • 9.3.5. Data Triangulation
    • 9.3.6. Top-Down Approach (Segment Wise Analysis)
    • 9.3.7. Bottom-Up Approach (Segmental Analysis)
  • 9.4. Assumptions and Limitations
  • 9.5. Data and Prediction Modelling

10. Annexures

  • 10.1. Recent Key Developments and Strategies
  • 10.2. Product Mapping
  • 10.3. Cancer Data Sheet

List of Tables

  • Table 1: Total Regional Geriatric Population by Region (%), 2015 and 2030
  • Table 2: Impact of Market Drivers
  • Table 3: Impact of Market Restraints
  • Table 4: Market Share (2014-2017)
  • Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
  • Table 1.2: GLOBOCAN Data as of 2012
  • Table 1.3: Common sites of Metastasis for Cancers
  • Table 1.4: Common Classes of Drugs Under Different Cancer Therapies
  • Table 1.5: Recent FDA Approvals of Oncology Drugs
  • Table 2.1: Impact of Market Drivers
  • Table 2.2: Impact of Market Restraints
  • Table 2.3: Comparison of R&D Expense 2017 and 2016
  • Table 2.4: Recent Approval of Metastatic Cancer Drugs
  • Table 2.5: Side Effects Caused by common Metastatic Cancer Drugs
  • Table 3.1: Regulatory Scenario Across the World
  • Table 3.2: Regulatory Designations Across The World
  • Table 3.3: Patent Landscape
  • Table 4.1: Factors Affecting the Bargaining Power of Suppliers
  • Table 4.2: Factors Affecting the Bargaining Power of Buyer
  • Table 4.3: Factors Affecting Threat of New Entrant
  • Table 4.4: Factors Affecting the Threat of Substitute
  • Table 4.5: Factors Affecting the Intensity of Competitive Rivalry
  • Table 4.6: Market Share of Key Players (2014-2017)
  • Table 4.7: Pipeline Analysis of Metastatic Cancer Treatment Drugs
  • Table 5.1: Estimated Incidence, Mortality, and Prevalence of Breast Cancer Worldwide in 2012
  • Table 5.2: Estimated Incidence and Mortality of Melanoma Worldwide in 2012
  • Table 5.3: Estimated Incidence, Mortality and Prevalence of Prostate Cancer Worldwide in 2012
  • Table 5.4: Estimated Incidence, Mortality and Prevalence of Lung Cancer (for both sexes) Worldwide in 2012
  • Table 5.5: Estimated Incidence, Mortality and Prevalence of Colorectal Cancer (for both sexes) Worldwide in 2012
  • Table 5.6: Estimated Incidence, Mortality and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
  • Table 5.7: List of Companies and Drugs for Various Therapeutic Indication
  • Table 6.1: List of Common Brand-name Drugs used to treat Metastatic Cancer
  • Table 6.2: List of Common Generic Drugs used to treat Metastatic Cancer
  • Table 6.3: Sales of Oncology Drugs
  • Table 7.1: State-wise distribution of Cancer in India
  • Table 8.1: List of Tier 1 and Tier 2 Companies
  • Table 8.2: AbbVie Inc.: Recent Developments
  • Table 8.3: Amgen, Inc.: Recent Developments
  • Table 8.4: AstraZeneca PLC: Recent Developments
  • Table 8.5: Bayer AG: Recent Developments
  • Table 8.6: Boehringer Ingelheim International GmbH: Recent Developments
  • Table 8.7: BRISTOL-MYERS SQUIBB COMPANY: Recent Developments
  • Table 8.8: CELGENE CORPORATION: Recent Developments
  • Table 8.9: Eli-Lilly and Company: Recent Developments
  • Table 8.10: F. Hoffmann-La Roche AG: Recent Developments
  • Table 8.11: JOHNSON & JOHNSON: Recent Developments
  • Table 8.12: Merck & Co.,Inc.: Recent Developments
  • Table 8.13: Novartis AG: Recent Developments
  • Table 8.14: Pfizer, Inc.: Recent Developments
  • Table 8.15: SANOFI: Recent Developments
  • Table 8.16: Takeda Pharmaceutical Company Limited: Recent Developments

List of Figures

  • Figure 1: Common Treatments of Cancer
  • Figure 2: Global Metastatic Cancer Treatment Market ($Million)
  • Figure 3: Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2017
  • Figure 4: Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2025
  • Figure 5: Global Metastatic Cancer Treatment Market by Products, 2017
  • Figure 6: Global Metastatic Cancer Treatment Market By Products, 2025
  • Figure 7: Global Metastatic Cancer Treatment Market by Region, 2017
  • Figure 8: Global Injectable Drug Delivery Market by Region, 2025
  • Figure 1.1: Causes of Cancer
  • Figure 1.2: Common Mechanism of Metastasis
  • Figure 1.3: Types of Metastatic Cancer (based on how far it has spread)
  • Figure 1.4: Global Metastatic Cancer Treatment Market, 2016-2025 ($ Million)
  • Figure 2.1: Market Dynamics: Drivers, Restraints & Opportunities
  • Figure 2.2: Targeted Therapies Designed for Different Cancer Types
  • Figure 3.1: Industry Insights (January 2014-February 2018)
  • Figure 4.1: Competitive Landscape (January 2014-February 2018)
  • Figure 4.2: Share of Key Developments and Strategies(January 2014 to March 2018)
  • Figure 4.3: Product Approvals by Companies
  • Figure 4.4: Clinical Study, by Companies
  • Figure 4.5: Product Approvals by Companies
  • Figure 4.6: Porter's Five Forces Analysis
  • Figure 5.1: Types of Metastatic Cancer by Therapeutic Indication
  • Figure 5.2: Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2014-2025 ($Million)
  • Figure 5.3: Signs and Symptoms of Metastatic Breast Cancer
  • Figure 5.4: Common Molecular Subtypes of Breast Cancer
  • Figure 5.5: Global Metastatic Cancer Treatment Market by Breast Cancer, 2014-2025 ($ Million)
  • Figure 5.6: List of Common Metastatic Breast Cancer Drugs
  • Figure 5.7: Signs and Symptoms of Metastatic Melanoma
  • Figure 5.8: Global Metastatic Cancer Treatment Market by Melanoma Cancer, 2014-2025 ($ Million)
  • Figure 5.9: List of Common Metastatic Melanoma Cancer Drugs
  • Figure 5.10: Signs and Symptoms of Metastatic Prostate Cancer
  • Figure 5.11: Global Metastatic Cancer Treatment Market by Prostate Cancer, 2014-2025 ($ Million)
  • Figure 5.12: List of Common Metastatic Prostate Cancer Drugs
  • Figure 5.13: Signs and Symptoms of Metastatic Lung Cancer
  • Figure 5.14: Global Metastatic Cancer Treatment Market by NSCLC, 2014-2025 ($ Million)
  • Figure 5.15: List of Common Metastatic Lung Cancer Drugs
  • Figure 5.16: Signs and Symptoms of Metastatic Colorectal Cancer
  • Figure 5.17: Global Metastatic Cancer Treatment Market by Colorectal Cancer, 2014-2025 ($ Million)
  • Figure 5.18: List of Common Metastatic Colorectal Cancer Drugs
  • Figure 5.19: Global Metastatic Cancer Treatment Market by Other Cancers, 2014-2025 ($ Million)
  • Figure 6.1: Classification of Anti-Cancer Drugs by Pharma Class
  • Figure 6.2: Global Metastatic Cancer Treatment Market by Branded Medicines, 2014-2025 ($ Million)
  • Figure 6.3: Global Metastatic Cancer Treatment Market by Generic Medicines, 2014-2025 ($ Million)
  • Figure 7.1: Global Metastatic Cancer Treatment Market by Region, 2014-2025 ($Million)
  • Figure 7.2: North America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
  • Figure 7.3: North America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
  • Figure 7.4: Cancer Patient Data by Cancers Type in the U.S. (2016)
  • Figure 7.5: Cancer Patient Data by Cancers Type in Canada (2016)
  • Figure 7.6: The U.S. Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.7: Canada Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.8: Europe Metastatic Cancer Treatment Market, 2014-2025 ($Million)
  • Figure 7.9: Europe Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
  • Figure 7.10: Cancer Patient Data by Cancers Type in Germany (2016)
  • Figure 7.11: Cancer Patient Data by Cancers Type in France (2016)
  • Figure 7.12: Cancer Patient Data by Cancers Type in Italy (2016)
  • Figure 7.13: France Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.14: Germany Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.15: Italy Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.16: Netherland Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.17: Switzerland Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.18: The U.K. Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.19: Spain Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.20: Sweden Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.21: Austria Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.22: Belgium Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.23: Denmark Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.24: Finland Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.25: Poland Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.26: Russia Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.27: Ireland Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.28: Rest of Europe Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.29: Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($Million)
  • Figure 7.30: Asia Pacific Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
  • Figure 7.31: Cancer Patient Data by Cancers Type in China (2016)
  • Figure 7.32: Cancer Patient Data by Cancers Type in Japan (2016)
  • Figure 7.33: Cancer Patient Data by Cancers Type in India (2016)
  • Figure 7.35: China Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.36: Japan Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.37: India Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.38: South Korea Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.39: Australia Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.40: Bangladesh Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.41: Malaysia Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.42: New Zealand Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.43: Rest of Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.44: Latin America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
  • Figure 7.45: Latin America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
  • Figure 7.46: Brazil Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.47: Mexico Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.48: Argentina Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.49: Rest of Latin America Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.50: Rest of the World (RoW) Metastatic Cancer Treatment Market, 2014-2025 ($Million)
  • Figure 7.51: Rest of the World (RoW) Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
  • Figure 7.52: Saudi Arabia Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.53: UAE Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.54: South Africa Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.55: Israel Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 7.56: Other Metastatic Cancer Treatment Market, 2014-2025 ($million)
  • Figure 8.1: Contribution of Various companies
  • Figure 8.2: AbbVie Inc.: Overall Product Portfolio
  • Figure 8.3: AbbVie Inc.: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.4: AbbVie Inc.: Overall Financials (2014-2017)
  • Figure 8.5: AbbVie Inc.: Revenue by Geography (2014-2017)
  • Figure 8.6: AbbVie Inc.: Global Presence
  • Figure 8.7: AbbVie Inc.: SWOT Analysis
  • Figure 8.8: Amgen, Inc.: Overall Product Portfolio
  • Figure 8.9: Amgen, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.10: Amgen, Inc.: Overall Financials (2014-2017)
  • Figure 8.11: Amgen, Inc.: Revenue by Geography (2014-2017)
  • Figure 8.12: Amgen, Inc.: Global Presence
  • Figure 8.13: Amgen, Inc.: SWOT Analysis
  • Figure 8.14: AstraZeneca PLC: Overall Product Portfolio
  • Figure 8.15: AstraZeneca PLC: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.16: AstraZeneca PLC: Overall Financials (2014-2017)
  • Figure 8.17: AstraZeneca PLC: Revenue by Product Sales (2014-2017)
  • Figure 8.18: AstraZeneca PLC: Revenue by Geography (2014-2017)
  • Figure 8.19: AstraZeneca PLC: Global Presence
  • Figure 8.20: AstraZeneca PLC: SWOT Analysis
  • Figure 8.21: Bayer AG: Overall Product Portfolio
  • Figure 8.22: Bayer AG: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.23: Bayer AG: Overall Financials (2014-2017)
  • Figure 8.24: Bayer AG: Revenue by Geography (2014-2017)
  • Figure 8.25: Bayer AG: Revenue by Business Segment (2014-2015)
  • Figure 8.26: Bayer AG: Revenue by Buisness Segment (2016-2017)
  • Figure 8.27: Bayer AG: Global Presence
  • Figure 8.28: Bayer AG: SWOT Analysis
  • Figure 8.29: Boehringer Ingelheim International GmbH: Overall Product Portfolio
  • Figure 8.30: Boehringer Ingelheim International GmbH: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.31: Boehringer Ingelheim International GmbH: Overall Financials (2014-2017)
  • Figure 8.32: Boehringer Ingelheim International GmbH: Revenue by Geography (2014-2017)
  • Figure 8.33: Boehringer Ingelheim International GmbH: Revenue by Business Segment (2014-2015)
  • Figure 8.34: Boehringer Ingelheim International GmbH: Revenue by Buisness Segment (2016-2017)
  • Figure 8.35: Boehringer Ingelheim International GmbH: Global Presence
  • Figure 8.36: Boehringer Ingelheim International GmbH: SWOT Analysis
  • Figure 8.37: BRISTOL-MYERS SQUIBB COMPANY: Overall Product Portfolio
  • Figure 8.38: BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.39: BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2017)
  • Figure 8.40: BRISTOL-MYERS SQUIBB COMPANY: Revenue by Geography (2014-2017)
  • Figure 8.41: BRISTOL-MYERS SQUIBB COMPANY: Global Presence
  • Figure 8.42: BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
  • Figure 8.43: CELGENE CORPORATION: Overall Product Portfolio
  • Figure 8.44: CELGENE CORPORATION: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.45: CELGENE CORPORATION: Overall Financials (2014-2017)
  • Figure 8.46: CELGENE CORPORATION: Revenue by Geography (2014-2017)
  • Figure 8.47: CELGENE CORPORATION: Global Presence
  • Figure 8.48: CELGENE CORPORATION: SWOT Analysis
  • Figure 8.49: Eli-Lilly and Company: Overall Product Portfolio
  • Figure 8.50: Eli-Lilly and Company: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.51: Eli-Lilly and Company: Overall Financials (2014-2017)
  • Figure 8.52: Eli-Lilly and Company: Revenue by Business segment (2014-2017)
  • Figure 8.53: Eli-Lilly and Company: Revenue by Geography (2014-2017)
  • Figure 8.54: Eli-Lilly and Company: Global Presence
  • Figure 8.55: Eli-Lilly and Company: SWOT Analysis
  • Figure 8.56: F. Hoffmann-La Roche AG: Overall Product Portfolio
  • Figure 8.57: F. Hoffmann-La Roche AG: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.58: F. Hoffmann-La Roche AG: Overall Financials (2014-2017)
  • Figure 8.59: F. Hoffmann-La Roche AG: Product Sales by Region (2014-2017)
  • Figure 8.60: F. Hoffmann-La Roche AG: Revenue by Division (2014-2017)
  • Figure 8.61: F. Hoffmann-La Roche AG: Revenue by Pharmaceutical Sub-Segment (2014-2017)
  • Figure 8.62: F. Hoffmann-La Roche AG: Global Presence
  • Figure 8.63: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 8.64: JOHNSON & JOHNSON: Overall Product Portfolio
  • Figure 8.65: JOHNSON & JOHNSON: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.66: JOHNSON & JOHNSON: Overall Financials (2014-2017)
  • Figure 8.67: JOHNSON & JOHNSON: Revenue by Business segment (2014-2017)
  • Figure 8.68: JOHNSON & JOHNSON: Revenue by Geography (2014-2017)
  • Figure 8.69: JOHNSON & JOHNSON: Global Presence
  • Figure 8.70: JOHNSON & JOHNSON: SWOT Analysis
  • Figure 8.71: Merck & Co., Inc.: Overall Product Portfolio
  • Figure 8.72: Merck & Co., Inc.: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.73: Merck & Co., Inc.: Overall Financials (2014-2017)
  • Figure 8.74: Merck & Co., Inc.: Revenue by Business segment (2014-2017)
  • Figure 8.75: Merck & Co., Inc.: Revenue by Geography (2014-2017)
  • Figure 8.76: Merck & Co., Inc.: Global Presence
  • Figure 8.77: Merck & Co., Inc.: SWOT Analysis
  • Figure 8.78: Novartis AG: Overall Product Portfolio
  • Figure 8.79: Novartis AG: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.80: Novartis AG: Overall Financials (2014-2017)
  • Figure 8.81: Novartis AG: Revenue by Geography (2014-2017)
  • Figure 8.82: Novartis AG: Revenue by Business Segment (2014-2015)
  • Figure 8.83: Novartis AG: Revenue by Buisness Segment (2016-2017)
  • Figure 8.84: Novartis AG: Global Presence
  • Figure 8.85: Novartis AG: SWOT Analysis
  • Figure 8.86: Pfizer, Inc.: Overall Product Portfolio
  • Figure 8.87: Pfizer, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.88: Pfizer, Inc.: Overall Financials (2014-2017)
  • Figure 8.89: Pfizer, Inc.: Revenue by Business segment (2014-2017)
  • Figure 8.90: Pfizer, Inc.: Revenue by Geography (2014-2017)
  • Figure 8.91: Pfizer, Inc.: Global Presence
  • Figure 8.92: Pfizer, Inc.: SWOT Analysis
  • Figure 8.93: SANOFI: Overall Product Portfolio
  • Figure 8.94: SANOFI: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.95: SANOFI: Overall Financials (2014-2017)
  • Figure 8.96: SANOFI: Revenue by Business Segment (2014-2015)
  • Figure 8.97: SANOFI: Revenue by Business Segment (2016-2017)
  • Figure 8.98: SANOFI: Revenue by Geography (2014-2015)
  • Figure 8.99: SANOFI: Revenue by Geography (2016-2017)
  • Figure 8.100: SANOFI: Global Presence
  • Figure 8.101: SANOFI: SWOT Analysis
  • Figure 8.102: Takeda Pharmaceutical Company Limited: Overall Product Portfolio
  • Figure 8.103: Takeda Pharmaceutical Company Limited: Product Portfolio for Metastatic Cancer Treatment Market
  • Figure 8.104: Takeda Pharmaceutical Company Limited: Overall Financials (2014-2017)
  • Figure 8.105: Takeda Pharmaceutical Company Limited: Revenue by Business segment (2014-2017)
  • Figure 8.106: Takeda Pharmaceutical Company Limited: Revenue by Geography (2014-2017)
  • Figure 8.107: Takeda Pharmaceutical Company Limited: Global Presence
  • Figure 8.108: Takeda Pharmaceutical Company Limited: SWOT Analysis
  • Figure 8.109: bluebird bio, Inc.: Product Pipeline for Cancer Treatment Market
  • Figure 8.110: Clovis Oncology, Inc.: Product Pipeline for Cancer Treatment Market
  • Figure 8.111: IDERA PHARMACEUTICALS, INC.: Product Pipeline for Cancer Treatment Market
  • Figure 8.112: eTheRNA immunotherapies NV: Product Pipeline for Cancer Treatment Market
  • Figure 9.1: Global Metastatic Cancer Treatment Market Segmentation
  • Figure 9.2: Considered Factors for Data Prediction & Modeling
Back to Top